Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $273.0 million for Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 40.78% year-over-year to $273.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.0 million (down 40.78% YoY) and the FY2025 annual result came in at $296.0 million, down 38.72% from the prior year.
• Non-Current Deferred Tax Liability fell to $273.0 million in Q1 2026, from $296.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $666.0 million in Q1 2022 and troughed at $273.0 million in Q1 2026.
• A 5-year average of $499.7 million and a median of $534.0 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability plunged 44.73% — and 2023, when it rose 10.58%.
• Tracing TEVA's Non-Current Deferred Tax Liability over 5 years: stood at $548.0 million in 2022, then rose by 10.58% to $606.0 million in 2023, then slipped by 20.3% to $483.0 million in 2024, then tumbled by 38.72% to $296.0 million in 2025, then declined by 7.77% to $273.0 million in 2026.
• Business Quant data shows TEVA's Non-Current Deferred Tax Liability at $273.0 million in Q1 2026, $296.0 million in Q4 2025, and $399.0 million in Q3 2025.